Department of Anesthesiology and Surgical Intensive Care Unit, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Department of Pathology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Front Endocrinol (Lausanne). 2021 Jan 8;11:593179. doi: 10.3389/fendo.2020.593179. eCollection 2020.
The majority of the critically ill patients may have critical illness-related corticosteroid insufficiency (CIRCI). The therapeutic effect of dexamethasone may be related to its ability to improve cortical function. Recent study showed that dexamethasone can reduce COVID-19 deaths by up to one third in critically ill patients. The aim of this article is to investigate whether SARS-CoV-2 can attack the adrenal cortex to aggravate the relative adrenal insufficiency.
We summarized the clinical features of COVID-19 reported in currently available observational studies. ACE2 and TMPRSS2 expression was examined in human adrenal glands by immunohistochemical staining. We retrospectively analyzed serum cortisol levels in critically ill patients with or without COVID-19.
High percentage of critically ill patients with SARS-COV-2 infection in the study were treated with vasopressors. ACE2 receptor and TMPRSS2 serine protease were colocalized in adrenocortical cells in zona fasciculata and zona reticularis. We collected plasma cortisol concentrations in nine critically ill patients with COVID-19. The cortisol levels of critically ill patients with COVID-19 were lower than those in non-COVID-19 critically ill group. Six of the nine COVID-19 critically ill patients had random plasma cortisol concentrations below 10 µg/dl, which met the criteria for the diagnosis of CIRCI.
We demonstrate that ACE2 and TMPRSS2 are colocalized in adrenocortical cells, and that the cortisol levels are lower in critically ill patients with COVID-19 as compared to those of non-COVID-19 critically ill patients. Based on our findings, we recommend measuring plasma cortisol level to guide hormonal therapy.
大多数危重症患者可能存在与危重症相关的皮质激素不足(CIRCI)。地塞米松的治疗效果可能与其改善皮质功能的能力有关。最近的研究表明,地塞米松可使危重症 COVID-19 患者的死亡率降低三分之一。本文旨在探讨 SARS-CoV-2 是否会攻击肾上腺皮质从而加重相对肾上腺功能不全。
我们总结了目前已发表的关于 COVID-19 的观察性研究中的临床特征。通过免疫组织化学染色检查人肾上腺中 ACE2 和 TMPRSS2 的表达。我们回顾性分析了伴有或不伴有 COVID-19 的危重症患者的血清皮质醇水平。
研究中感染 SARS-COV-2 的危重症患者中,很大比例的患者接受了升压治疗。ACE2 受体和 TMPRSS2 丝氨酸蛋白酶在束状带和网状带的肾上腺皮质细胞中存在共定位。我们收集了 9 例 COVID-19 危重症患者的血浆皮质醇浓度。COVID-19 危重症患者的皮质醇水平低于非 COVID-19 危重症组。9 例 COVID-19 危重症患者中有 6 例随机血浆皮质醇浓度低于 10 µg/dl,符合 CIRCI 的诊断标准。
我们证明 ACE2 和 TMPRSS2 在肾上腺皮质细胞中存在共定位,COVID-19 危重症患者的皮质醇水平低于非 COVID-19 危重症患者。基于我们的发现,我们建议测量血浆皮质醇水平以指导激素治疗。